PURPOSE: Pivalic acid (PVA) forms conjugates with endogenous carnitine and enhances its excretion. The purpose of this study is to determine whether tissue carnitine levels decrease in parallel with plasma levels in carnitine deficiency induced by PVA. METHODS: PVA was orally administered to rats for 5 days. Carnitine levels in plasma, liver, kidney, muscle, and heart were monitored. The tissue uptake clearance (CLuptake) was determined in vivo by the integration plot method. Hepatocytes were prepared from control and PVA-treated rats, and the uptake of L-carnitine was determined. RESULTS: Plasma concentrations of L-carnitine decreased as a result of the enhanced carnitine elimination as pivaloylcarnitine (PCN) when rats were treated with PVA. However, L-carnitine concentrations in liver, muscle, and heart remained relatively constant during the study. period. CLuptake increased in liver and muscle and, thus, the rate of carnitine uptake from plasma into these tissues did not change even at low plasma concentrations. This helps maintain carnitine levels in these tissues. Up-regulation of carnitine transporters is suggested to be a mechanism for the increased CLuptake. CONCLUSIONS: In the carnitine deficiency state induced by PVA, increased CLuptake owing to up-regulation of carnitine transporters is suggested to help maintain carnitine levels in some tissues.
PURPOSE:Pivalic acid (PVA) forms conjugates with endogenous carnitine and enhances its excretion. The purpose of this study is to determine whether tissue carnitine levels decrease in parallel with plasma levels in carnitine deficiency induced by PVA. METHODS:PVA was orally administered to rats for 5 days. Carnitine levels in plasma, liver, kidney, muscle, and heart were monitored. The tissue uptake clearance (CLuptake) was determined in vivo by the integration plot method. Hepatocytes were prepared from control and PVA-treated rats, and the uptake of L-carnitine was determined. RESULTS: Plasma concentrations of L-carnitine decreased as a result of the enhanced carnitine elimination as pivaloylcarnitine (PCN) when rats were treated with PVA. However, L-carnitine concentrations in liver, muscle, and heart remained relatively constant during the study. period. CLuptake increased in liver and muscle and, thus, the rate of carnitine uptake from plasma into these tissues did not change even at low plasma concentrations. This helps maintain carnitine levels in these tissues. Up-regulation of carnitine transporters is suggested to be a mechanism for the increased CLuptake. CONCLUSIONS: In the carnitine deficiency state induced by PVA, increased CLuptake owing to up-regulation of carnitine transporters is suggested to help maintain carnitine levels in some tissues.
Authors: X Wu; W Huang; P D Prasad; P Seth; D P Rajan; F H Leibach; J Chen; S J Conway; V Ganapathy Journal: J Pharmacol Exp Ther Date: 1999-09 Impact factor: 4.030
Authors: K Yokogawa; Y Higashi; I Tamai; M Nomura; N Hashimoto; H Nikaido; J Hayakawa; K Miyamoto; A Tsuji Journal: J Pharmacol Exp Ther Date: 1999-04 Impact factor: 4.030
Authors: Sarah E Seiler; Ola J Martin; Robert C Noland; Dorothy H Slentz; Karen L DeBalsi; Olga R Ilkayeva; Jie An; Christopher B Newgard; Timothy R Koves; Deborah M Muoio Journal: J Lipid Res Date: 2014-01-06 Impact factor: 5.922
Authors: Robert C Noland; Timothy R Koves; Sarah E Seiler; Helen Lum; Robert M Lust; Olga Ilkayeva; Robert D Stevens; Fausto G Hegardt; Deborah M Muoio Journal: J Biol Chem Date: 2009-06-24 Impact factor: 5.157